Mylan launches generic Avodart capsules in US
Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for
THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement to further the development of two drug candidates, Batten-1 and TX01, targeted at the Batten, Gaucher, and Niemann-Pick type C rare diseases.
The RAC also issued recommendations on several design elements of the research and clinical development program. DTX301 is an adeno-associated virus (AAV) gene therapy product being developed to